<DOC>
	<DOCNO>NCT01633970</DOCNO>
	<brief_summary>This open-label , Phase Ib study six treatment arm design assess safety , pharmacology preliminary efficacy atezolizumab ( MPDL3280A ; engineer anti-programmed death-ligand 1 [ PDL1 ] antibody ) administer bevacizumab ( Arm A ) bevacizumab plus oxaliplatin , leucovorin , 5-fluorouracil ( 5-FU ) ( FOLFOX ) ( Arm B ) , carboplatin paclitaxel ( Arm C ) , carboplatin pemetrexed ( Arm D ) , carboplatin nab-paclitaxel ( Arm E ) , nab-paclitaxel ( Arm F ) participants locally advanced metastatic solid tumor . The study include dose escalation cohort establish maximum tolerate dose ( MTD ) maximum administer dose ( MAD ) expansion cohort initiate base select dose level MTD MAD .</brief_summary>
	<brief_title>A Study Atezolizumab Administered Combination With Bevacizumab and/or With Chemotherapy Participants With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>General Histologically cytologically document advanced solid tumor Adequate hematologic end organ function Measurable disease RECIST v1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Resolution acute , clinically significant treatmentrelated toxicity prior therapy Grade le equal ( &lt; /= ) 1 prior study entry , exception alopecia Eligible Tumor Types : Arm A Escalation Cohorts Arms A B Biopsy Cohort ( Cutaneous/Subcutaneous Lesions ) Histologically cytologically document , incurable metastatic solid malignancy fail available acceptable standard therapy participant eligible Arm A B Safety Expansion Cohorts , Arm B Escalation Cohorts , Arm B Biopsy Cohort ( Liver Lesions ) Histologically cytologically confirm metastatic colorectal cancer ( mCRC ) . Participants Arm A Safety Expansion Cohort must mCRC establish therapy prove ineffective intolerable . Participants malignancy mCRC within 5 year prior Day 1 ( except negligible risk metastasis death , adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat surgically curative intent , ductal carcinoma situ treat surgically curative intent ) eligible . Arm A renal cell carcinoma ( RCC ) Cohort : Histologically cytologically confirm advanced metastatic RCC clear cell component . Arm A Tumor TypeSpecific Cohort : Gastric Cancer : Histologically cytologically confirm locally advanced metastatic adenocarcinoma stomach gastroesophageal junction establish therapy prove ineffective intolerable . The decision may make restrict enrollment participant specify tumor PDL1 status ( e.g. , immunohistochemistry [ IHC ] status 0/1 2/3 ) Ovarian Cancer : Measurable/assessable ovarian cancer ( define epithelial ovarian , fallopian tube , primary peritoneal cancer ) progress less ( &lt; ) 6 month complete platinumbased therapy . The following histological type eligible : Adenocarcinoma NOS , clear cell adenocarcinoma , endometriod adenocarcinoma , malignant Brenner 's tumour , mixed epithelial carcinoma , mucinous adenocarcinoma , serous adenocarcinoma , transitional cell carcinoma , undifferentiated carcinoma Bladder Cancer : Histologically cytologically document locally advanced ( T4b , N ; T , N 23 ) metastatic ( M1 , Stage IV ) transitional cell carcinoma urothelium ( include renal pelvis , ureter , urinary bladder , urethra ) Participants mixed histology require dominant transitional cell pattern Locally advance bladder cancer must inoperable base involvement pelvic sidewall adjacent viscera ( clinical stage T4b ) bulky nodal metastasis ( N2N3 ) Disease progression follow treatment least one platinumcontaining regimen ( e.g. , GC , MVAC , CarboGem , etc . ) inoperable locally advanced metastatic urothelial carcinoma disease recurrence Cervical Cancer : Persistent recurrent squamous cell carcinoma cervix ( include adenosquamous tumor ) Arms C , D , E Cohorts : Histologically cytologically document Stage IIIB ( eligible definitive chemoradiotherapy ) , Stage IV , recurrent nonsmall cell lung cancer ( NSCLC ) Arm F Cohort : Histologically confirm estrogen receptor ( ER ) , progesterone receptor ( PR ) , human epidermal growth factor receptor ( HER ) negative ( triplenegative ) adenocarcinoma breast treat systemic cytotoxic therapy . Locally recurrent disease must amenable resection curative intent Participants tumor amenable excisional , punch , core needle biopsy eligible separate biopsy expansion cohort Tumor molecular status : Arm A safety expansion cohort Up 10 participant CRC high microsatellite instability ( MSIH ) may enrol General Exclusions Any approve anticancer therapy , include chemotherapy , hormonal therapy , radiotherapy , herbal therapy intend anticancer therapy , within 3 week prior initiation study treatment ; follow allow : hormonal therapy gonadotropinreleasing hormone agonist antagonists prostate cancer , hormonereplacement therapy , palliative radiotherapy bone metastases great ( &gt; ) 2 week prior Day 1 Bisphosphonate therapy symptomatic hypercalcemia Known clinically significant liver disease Known primary central nervous ( CNS ) malignancy active CNS metastasis ( progress require anticonvulsant corticosteroid symptomatic control ) Pregnant lactate woman Known hypersensitivity Chinese hamster ovary cell product component atezolizumab formulation History autoimmune disease , idiopathic pulmonary fibrosis , human immunodeficiency virus ( HIV ) , hepatitis B C infection ; history hepatitis B allow infection resolve ( absence hepatitis B surface antigen [ HBsAg ] ) Severe infection within 4 week prior Day 1 , sign symptom significant infection within 2 week prior Day 1 Received oral IV antibiotic within 2 week prior Cycle 1 Day 1 History myocardial infarction , unstable angina stroke transient ischemic attack within 6 month prior Day 1 Administration live , attenuate vaccine within 4 week Day 1 anticipation live attenuated vaccine require study BevacizumabSpecific Exclusions ( Arms A B ) Exclusion Criteria Unique Arm A RCC Cohort Any prior systemic treatment ( include tyrosine kinase inhibitor , antibody therapy , immunotherapy , chemotherapy , hormonal therapy , investigational therapy ) RCC . All treatment , neoadjuvant , adjuvant , locally advanced metastatic RCC permit Arm A Tumor TypeSpecific Cohort : Gastric Cancer : Prior approve experimental antivascular endothelial growth factor receptor ( VEGF/VEGFR ) therapy ( include , example , bevacizumab nintedanib ) . The decision may make allocate specified number slots participant receive prior antiVEGF/VEGFR therapy Ovarian Cancer : Refractory disease History bowel obstruction &gt; 2 prior anticancer regimens Prior approve experimental antiVEGF/VEGFR therapy ( include , example , bevacizumab nintedanib ) Cervical Cancer : &gt; 2 prior cytotoxic regimen , include prior cisplatinbased chemotherapy concomitantly administer primary pelvic radiation Exclusion Criteria Unique Arm B : Prior treatment oxaliplatincontaining regimen . Oxaliplatin &gt; 12 month prior diagnosis metastatic disease permit . Known dihydropyrimidine dehydrogenase deficiency thymidylate synthase gene polymorphism predispose participant 5FU toxicity Exclusion Criteria Unique Arms C , D , E : Prior chemotherapy locally advance metastatic NSCLC For participant receive prior adjuvant/neoadjuvant chemotherapy chemoradiation NSCLC , treatmentfree interval &gt; 6 month last treatment administration date recurrence required Participants know epidermal growth factor receptor ( EGFR ) sensitize mutation must experience disease progression treatment approve EGFR tyrosine kinase inhibitor Participants know anaplastic lymphoma kinase ( ALK ) fusion oncogene must experience disease progression treatment crizotinib For Arm D ( carboplatin + pemetrexed ) , squamous cell histology evidence mixed NSCLC histology predominance squamous cell type For Arm D ( carboplatin + pemetrexed ) , inability discontinue treatment nonsteroidal antiinflammatory drug ( NSAIDs ) 5 day Exclusion Criteria Unique Arm F : Prior therapy two cytotoxic regimen metastatic locally advanced triplenegative breast cancer ( TNBC ) Treatment taxanecontaining regimen within 6 month enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>